drugset / Trial / NCT06879041

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06879041

Phase 1 Recruiting 136 enrolled AstraZeneca Parexel · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Timeline

Start
2025-03-10
Primary completion
2029-04-16
Completion
2029-04-16

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2275 Unknown
Subject AZD2284 Unknown
Subject AZD2287 Diagnostic / imaging agent